Monday, September 19, 2022 12:15:16 PM
The private placement was led by Redmile Group, with participation by Boxer Capital, Braidwell LP, EcoR1 Capital, Vivo Capital, Great Point Partners, LLC, Adage Capital Management, Logos Capital, Maven Investment Partners US, Driehaus Capital Management, Acuta Capital Partners, CaaS Capital Management, Woodline Partners LP, Walleye Capital and other investors, including two large mutual funds.
Ventyx currently intends to use the net proceeds from the proposed private placement, together with existing cash and cash equivalents, to fund the clinical development of VTX958, VTX002, VTX2735 and VTX3232, the preclinical development of other programs, research activities and working capital and other general corporate purposes. With the proceeds from the private placement, Ventyx expects to extend its cash runway into 2025. This cash estimate is a preliminary estimate and is based on information available to management as of the date of this private placement, and these estimates could change.
New York Yankees and Duke Basketball
Recent VTYX News
- Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024 • GlobeNewswire Inc. • 05/02/2024 08:05:00 PM
- The Gross Law Firm Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Ventyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 30, 2024 to Discuss Your Rights - VTYX • PR Newswire (US) • 04/19/2024 10:00:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Biosciences, Inc. Lawsuit - VTYX • PR Newswire (US) • 04/16/2024 09:45:00 AM
- The Gross Law Firm Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Investors in Ventyx Biosciences, Inc. Should Contact The Gross Law Firm Before April 30, 2024 to Discuss Your Rights - VTYX • PR Newswire (US) • 04/09/2024 10:10:00 AM
- Investors who lost money on Ventyx Biosciences, Inc.(VTYX) should contact The Gross Law Firm about pending Class Action - VTYX • PR Newswire (US) • 04/05/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Biosciences, Inc. Lawsuit - VTYX • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Ventyx Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - VTYX • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 01:01:59 PM
- Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event • GlobeNewswire Inc. • 03/11/2024 11:00:00 AM
- The Gross Law Firm Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX • PR Newswire (US) • 03/11/2024 09:45:00 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/08/2024 09:05:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:45:01 PM
- Ventyx Biosciences Announces $100 Million Private Placement of Common Stock • GlobeNewswire Inc. • 03/07/2024 01:00:19 PM
- Class Action Filed Against Ventyx Biosciences, Inc. (VTYX) Seeking Recovery for Investors - Contact The Gross Law Firm • PR Newswire (US) • 03/07/2024 10:45:00 AM
- Ventyx Biosciences to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 03/06/2024 01:00:00 PM
- Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024 • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:08:05 PM
- Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress • GlobeNewswire Inc. • 02/27/2024 09:01:00 PM
- Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO) • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- Form POSASR - Post-effective Amendment to an automatic shelf registration statement • Edgar (US Regulatory) • 02/13/2024 09:09:32 PM
- Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/06/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 11:26:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 11:23:42 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM